Search

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

EHA-Balkan Hematology Day 2021

EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 2nd edition of the EHA-Balkan Hematology Day.

Read more

EHA-AAH joint membership

Save money and time by becoming a joint member of EHA and the Albanian Association of Hematology. We've joined forces with the Albanian Association of Hematology (AAH) to offer a special joint membership deal.

Read more

EHA-AHA joint membership

Save money and time by becoming a joint member of EHA and the Armenian Hematology Association. We've joined forces with the Armenian Hematology Association (AHA) to offer a special joint membership deal.

Read more

EHA-BMSH joint membership

Save money and time by becoming a joint member of EHA and the Bulgarian Medical Society of Hematology. We've joined forces with the Bulgarian Medical Society of Hematology (BMSH) to offer a special joint membership deal.

Read more

EHA-MHTT joint membership

Save money and time by becoming a joint member of EHA and the Magyar Hematológiai és Transzfuziológiai Társaság. We've joined forces with the Magyar Hematológiai és Transzfuziológiai Társaság (MHTT) to offer a special joint membership deal.

Read more